
Ahmad Nanaa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9630314/publications.pdf Version: 2024-02-01



Δημαρ Νανία

#	Article	IF	CITATIONS
1	Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation. Blood Cancer Journal, 2021, 11, 49.	6.2	28
2	Genetic features and clinical outcomes of patients with isolated and comutated <i>DDX41</i> -mutated myeloid neoplasms. Blood Advances, 2022, 6, 528-532.	5.2	27
3	Machine learning and augmented human intelligence use in histomorphology for haematolymphoid disorders. Pathology, 2021, 53, 400-407.	0.6	12
4	Treatment outcome of clonal cytopenias of undetermined significance: a single-institution retrospective study. Blood Cancer Journal, 2021, 11, 43.	6.2	11
5	Clinical and biological characteristics and prognostic impact of somatic GATA2 mutations in myeloid malignancies: a single institution experience. Blood Cancer Journal, 2021, 11, 122.	6.2	7
6	Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms. Blood Cancer Journal, 2022, 12, .	6.2	7
7	Classification of Monocytes, Promonocytes and Monoblasts Using Deep Neural Network Models: An Area of Unmet Need in Diagnostic Hematopathology. Journal of Clinical Medicine, 2021, 10, 2264.	2.4	5
8	Clinical Characteristics and Prognosis of Thirty-Three Patients with Myeloid Neoplasms and DDX41 Mutation: Mayo Clinic Experience. Blood, 2021, 138, 3691-3691.	1.4	1
9	Predictors of Survival and Time to Progression to Myeloid Neoplasm in Patients with Clonal Cytopenias. Blood, 2020, 136, 26-27.	1.4	1
10	Treatment Outcome for Symptomatic Patients with Clonal Cytopenia of Undetermined Significance: A Single-Institution Retrospective Study. Blood, 2020, 136, 44-44.	1.4	0
11	Characteristics and prognosis of mutated <i>STAG2</i> myeloid neoplasms Journal of Clinical Oncology, 2022, 40, e19014-e19014.	1.6	0
12	Characteristics and prognosis of <i>DDX41</i> and <i>GATA2</i> mutated myeloid neoplasms Journal of Clinical Oncology, 2022, 40, e19010-e19010.	1.6	0